Alnylam Pharmaceuticals announced positive results from its ILLUMINATE-A Phase III trial investigating lumasiran for the treatment of Primary Hyperoxaluria Type 1 (PH1). The trial met its primary efficacy endpoint and all tested secondary endpoints. Alnylam...